Agency for Science, Technology and Research

Chugai Seiyaku Kabushiki Kaisha

National University of Singapore

Cheng-I Wang

Siok Ping Yeo

Hsueh Ling Janice Oh

Hwee Ching Tan

Angeline Goh

Florent Ginhoux

John Edward Connolly

Peter Brauer

Alessandra Rosa Mortellaro

Subhra Kumar Biswas

Pingyu Zhong

Jianrong Lionel Low

Yun Pei Sharon Goh

Katja Fink

Lucile Warter

Jean-Pierre Abastado

Alessandra Nardin

Eve Ngoh

Paul Macary

Roland Zuest

Lisa Fong Poh Ng

Laurent Renia

Yee Chin Yvonne Yeap

Meihui Xu

Ching-Wen Huang

Bei Wang

Zi Xian Eve Ngoh

Wen-Hsin Lee

Lionel Jianrong Low

Sandy Wen-Hsin Lee

Zenjiro Sampei

Xing'er Christine Xoo

Hsueh Ling Oh

We describe an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (V) sequence and a light chain variable region (V) sequence of a clone selected from: 5C4, 4H1, 1D2, 1C4, 2B5, 1F1, 1H1, 4A5, 1D8, 1D3, 2F1, 3C6, 3D12, 3A9, 1F4, 1H10, 3C12, 4G11, 4A12, 1A12, 3G12, 4F9, 4G4 and 1E1 which is capable of specifically binding to glypican-3 (GPC-3) (GenBank Accession Number: NP_004475.1), or a sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.

Glypican-3 (GPC-3) antibodies

Antibodies, antigen-binding fragments and polypeptides that bind to HER2 are disclosed, as well as nucleic acids and vectors encoding the same. Also provided are cells comprising the antibodies, antigen-binding fragments, polypeptides, nucleic acids and vectors, methods of making such molecules, and the use of such molecules for therapeutic applications.

Anti-HER2 antibodies

The present invention is directed to antigen binding proteins and in particular to IL-1β antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.

IL-1β neutralizing human monoclonal antibodies

The disclosure provides anti-DENV antibodies having a cross-reactivity to ZIKV and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection.

Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use

The present invention is directed to antigen binding proteins and in particular to IL-1&#x3b2; antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.

IL-1&#x3b2; neutralizing human monoclonal antibodies

Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

Anti-PD-L1 antibodies

Anti-CTLA-4 antibodies are disclosed. Also disclosed are compositions comprising such antibodies, and uses and methods using the same.

Anti-CTLA-4 antibodies

Anti-TIM-3 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

Anti-TIM-3 antibodies

Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

Anti-PD-1 antibodies

Method of reducing tumor growth with IL-1beta neutralizing human monoclonal antibodies

Anti-CD122 and/or &#x3b3;c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

IL2R common gamma chain antibodies

Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and methods of using such antibodies to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.

IL2Rbeta/common gamma chain antibodies

Method for expansion of a population of cells with IL2R beta/common gamma chain antibodies

Growing community of inventors

Singapore, Singapore

Cheng-I Wang